Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a sell rating to a strong sell rating in a report published on Saturday,Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on VYGR. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a report on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $16.50.

Voyager Therapeutics Price Performance

NASDAQ:VYGR opened at $1.86 on Friday. The business’s 50-day moving average is $2.55 and its two-hundred day moving average is $3.41. Voyager Therapeutics has a 12 month low of $1.68 and a 12 month high of $5.48. The firm has a market capitalization of $114.92 million, a PE ratio of -1.08 and a beta of 1.20.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.01. The company had revenue of $0.61 million during the quarter, compared to the consensus estimate of $6.35 million. Voyager Therapeutics had a negative return on equity of 59.83% and a negative net margin of 416.32%. Equities analysts anticipate that Voyager Therapeutics will post -1.63 EPS for the current year.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VYGR. Opaleye Management Inc. grew its stake in Voyager Therapeutics by 3.0% during the 2nd quarter. Opaleye Management Inc. now owns 1,185,000 shares of the company’s stock valued at $4,148,000 after purchasing an additional 35,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $73,000. Spark Investment Management LLC purchased a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $47,000. Seven Fleet Capital Management LP increased its holdings in Voyager Therapeutics by 100.0% during the 2nd quarter. Seven Fleet Capital Management LP now owns 230,406 shares of the company’s stock worth $772,000 after purchasing an additional 115,203 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $158,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.